Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Rating Upgraded by Kepler Capital Markets

Kepler Capital Markets upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Free Report) from a hold rating to a buy rating in a research report report published on Wednesday, Marketbeat.com reports.

Other equities research analysts have also recently issued reports about the company. The Goldman Sachs Group raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. Hsbc Global Res raised Bayer Aktiengesellschaft to a "hold" rating in a research report on Monday, April 28th. Finally, Wall Street Zen raised Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Bayer Aktiengesellschaft currently has an average rating of "Buy".

Bayer Aktiengesellschaft Price Performance

OTCMKTS:BAYRY traded down $0.16 during mid-day trading on Wednesday, reaching $7.87. The stock had a trading volume of 385,705 shares, compared to its average volume of 807,125. The firm has a 50 day moving average price of $6.67 and a two-hundred day moving average price of $5.96. The stock has a market capitalization of $30.93 billion, a P/E ratio of -30.27 and a beta of 0.85. Bayer Aktiengesellschaft has a one year low of $4.79 and a one year high of $8.58. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.81 and a current ratio of 1.32.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported $0.65 EPS for the quarter, topping analysts' consensus estimates of $0.63 by $0.02. The business had revenue of $15.27 billion for the quarter, compared to analysts' expectations of $13.39 billion. Bayer Aktiengesellschaft had a positive return on equity of 16.90% and a negative net margin of 2.02%. As a group, analysts expect that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Bayer Aktiengesellschaft Increases Dividend

The company also recently disclosed a dividend, which was paid on Monday, May 12th. Stockholders of record on Wednesday, April 30th were paid a $0.0224 dividend. This represents a dividend yield of 0.38%. This is a boost from Bayer Aktiengesellschaft's previous dividend of $0.02. The ex-dividend date of this dividend was Tuesday, April 29th. Bayer Aktiengesellschaft's dividend payout ratio (DPR) is presently -2.17%.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.